Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness continues acquisition spree

This article was originally published in The Gray Sheet

Executive Summary

Waltham, Mass.-based Inverness Medical Innovations acquires home diagnostic services provider Quality Assured Services for $25 million in cash and stock, the companies announce June 18. The deal with the privately held Florida firm "provides Inverness with an established in-home patient service and distribution network and a leadership position in the prescription self-testing market, especially in coagulation monitoring," Inverness says. The acquisition follows Inverness agreements this year to buy heart test maker Biosite for $1.58 billion, as well as Cholestech, First Check Diagnostics and 75% of Instant Technologies (1"The Gray Sheet" June 11, 2007, p. 9)...

You may also be interested in...



Mergers & Acquisitions In Brief

Ecolab's Microtek deal focuses on infection prevention: Acquisition of Microtek Medical for $274 million is intended to expand Ecolab's infection prevention offerings, Ecolab announces Aug. 7. Microtek's surgical drapes, disposable linens, and fluid and medical waste management equipment will dovetail with Ecolab's surface disinfectants, instrument cleaning detergents and surgical hand scrubs. Microtek reported second quarter revenue of $38.5 million, up 6.8%. Ecolab, with Q2 sales of $1.4 billion (up 11%) bills itself as "the world's leading provider of cleaning, food safety and health protection products and services". Ecolab will pay $6.30 in cash for each of Microtek's 43.5 million shares outstanding - representing a 34% premium over Microtek stock's Aug. 7 closing price of $4.69...

Mergers & Acquisitions In Brief

Biomet update: The private equity group attempting to buy Biomet has increased its bid from $44 per share to $46 per share, or $10.9 billion to $11.4 billion, and has commenced a tender offer to acquire all outstanding shares. The tender offer, announced June 7 and set to begin on or before June 14, prevents the shareholder vote on the deal that had been scheduled for June 8. According to Biomet, if 75%-90% of share holders accept the tender offer within 20 business days, the deal will go to a shareholder vote. If over 90% of shareholders accept the offer, the deal will go through without a vote. The Institutional Shareholder Services released a report May 29 advising shareholders not to accept the $44 per share offer because it represented a "takeover premium" too low to justify giving up control of the company (1"The Gray Sheet" June 4, 2007, p. 4)...

Teva Plans To Appeal EU Provigil Fine

Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel